Literature DB >> 6295429

Interaction of misonidazole and WR-2721--II. Modification of tumour radiosensitization.

A Rojas, F A Stewart, J Denekamp.   

Abstract

Two types of mouse tumour have been used to study the radiomodifying actions of Misonidazole (MISO) and WR-2721 when used alone and in combination with each other. Single dose studies were performed in both of the tumours and fractionated studies were performed on the anaplastic carcinoma, CA MT. Radioprotection with WR-2721 was seen in both tumours, being most marked at low X-ray doses. The protection was more obvious and the sensitization by MISO less in the fractionated experiment. The combination of MISO and WR-2721 gave an intermediate response compared with either drug used alone, resulting in some sensitization with single doses and an overall protection with repeated small doses. An interactive toxicity of the 2 drugs was also observed, suggesting an additive effect when assessed in terms of lethality. These studies indicate that the effects of both MISO and WR-2721 are dependent upon the oxygen status of the cells in the tumour, and that MISO can act in an oxygen-mimetic manner to modify the radioprotection observed with WR-2721.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6295429      PMCID: PMC2011240          DOI: 10.1038/bjc.1983.8

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  The modification of tissue response to radiation injury.

Authors:  O C SCOTT
Journal:  Annu Rev Med       Date:  1963       Impact factor: 13.739

2.  The neurotoxicity of misonidazole: pooling of data from five centres.

Authors:  S Disch; M I Saunders; P Anderson; R C Urtasun; K H Karcher; H D Kogelnik; N Bleehen; T L Phillips; T H Wasserman
Journal:  Br J Radiol       Date:  1978-12       Impact factor: 3.039

3.  Some pharmacologic effects of WR-2721: their role in toxicity and radioprotection.

Authors:  J M Yuhas; J O Proctor; L H Smith
Journal:  Radiat Res       Date:  1973-05       Impact factor: 2.841

4.  Thiol radioprotection in vivo: the critical role of tissue oxygen concentration.

Authors:  J Denekamp; B D Michael; A Rojas; F A Stewart
Journal:  Br J Radiol       Date:  1981-12       Impact factor: 3.039

5.  Correlation between the radiobiological oxygen constant, K, and the non-protein sulphydryl content of mammalian cells.

Authors:  B M Cullen; A Michalowski; H C Walker; L Révész
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1980-11

6.  Radioprotection of mouse skin by WR-2721: the critical influence of oxygen tension.

Authors:  J Denekamp; B D Michael; A Rojas; F A Stewart
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982 Mar-Apr       Impact factor: 7.038

7.  Influence of WR 2721 on the efficacy of radiotherapy and chemotherapy of murine tumors.

Authors:  J J Clement; R K Johnson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982 Mar-Apr       Impact factor: 7.038

8.  Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum.

Authors:  M M Kligerman; A L Blumberg; J H Glick; D F Nelson; D Glover; J M Yuhas; H I Amols; R L Goodman
Journal:  Cancer Clin Trials       Date:  1981

9.  Modification of the oral radiation death syndrome with combined WR-2721 and misonidazole.

Authors:  P Grigsby; Y Maruyama
Journal:  Br J Radiol       Date:  1981-11       Impact factor: 3.039

10.  Skin sensitization by misonidazole: a demonstration of uniform mild hypoxia.

Authors:  F A Stewart; J Denekamp; V S Randhawa
Journal:  Br J Cancer       Date:  1982-06       Impact factor: 7.640

View more
  2 in total

Review 1.  Modifiers of radiosensitivity.

Authors:  A Rojas; J Denekamp
Journal:  Experientia       Date:  1989-01-15

Review 2.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.